Cambrian BioPharma Inc - 04 Dec 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
10%+ Owner
Signature
Cambrian BioPharma Inc, by: /s/ James Peyer
Issuer symbol
SNSE
Transactions as of
04 Dec 2025
Net transactions value
-$232,690
Form type
4
Filing time
08 Dec 2025, 16:39:10 UTC
Previous filing
23 May 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cambrian BioPharma Inc 10%+ Owner 228 PARK AVENUE S., #66643, NEW YORK Cambrian BioPharma Inc, by: /s/ James Peyer 08 Dec 2025 0001797409

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Sale $45,300 -5,000 -2.7% $9.06 177,654 04 Dec 2025 Direct F1, F2, F3
transaction SNSE Common Stock Sale $165,391 -14,508 -8.2% $11.40 163,146 05 Dec 2025 Direct F3, F4
transaction SNSE Common Stock Sale $21,446 -1,745 -1.1% $12.29 161,401 05 Dec 2025 Direct F3, F5
transaction SNSE Common Stock Sale $553 -42 -0.03% $13.16 161,359 05 Dec 2025 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.
F3 These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F4 The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.